Clinical trials: Diabetic Macular Edema
Diabetic Macular Edema
Phase II Combination Steroid and Anti-VEGF for Persistent DME
Although anti-vascular endothelial growth factor (VEGF) therapy is generally effective as treatment for center-involved diabetic macular edema (DME), a substantial proportion of anti-VEGF-treated eyes with DME do not achieve…
- Trial name
- NCT01945866
- Testing
- intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant
- Where
- 56 sites in United States
- Volunteers
- 129 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Diabetic Macular Edema
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
To determine if there is visual benefit with Ozurdex treatment every three months compared to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema.
- Trial name
- NCT02036424
- Testing
- Ozurdex, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Raj K. Maturi, MD
Diabetic Macular Edema
A Study to Evaluate the Safety and Tolerability of EXN407
This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved…
- Trial name
- NCT04565756
- Testing
- EXN407
- Where
- 11 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Exonate Limited
Diabetic Macular Edema
Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies
It is well known that blindness is one of the most feared disabilities expressed by patients in the United States. Estimates of the economic impact of visual disability in the current population exceed 30 million US dollars in…
- Trial name
- NCT00779142
- Testing
- Methotrexate intravenous 25mg/ml
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University
Diabetic Macular Edema
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema.
- Trial name
- DIME (NCT02471651)
- Testing
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
DIABETIC MACULAR EDEMA
Triamcinolone vs. Laser for Diabetic Macular Edema
The purpose of this study is to determine if intravitreal triamcinolone acetonide (IVTA) injection at the time of cataract surgery will improve visual acuity and decrease post-operative swelling in diabetic patients requiring…
- Trial name
- IVTA (NCT00229931)
- Testing
- Triamcinolone acetonide, laser
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Oklahoma
Diabetic Retinopathy, Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
- Trial name
- SwapTwo (NCT02559180)
- Testing
- aflibercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rishi Singh
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
- Trial name
- RESOLVE (NCT00284050)
- Testing
- Ranibizumab 0.3 mg, Ranibizumab 0.5 mg
- Where
- Switzerland
- Volunteers
- 151 people
- Sponsor
- Novartis
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Diabetic Macular Edema
Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
The investigators hypothesize that a combination treatment with Avastin and Ozurdex will result in a more rapid improvement of visual acuity compared to the use of Avastin alone.
- Trial name
- NCT01309451
- Testing
- Bevacizumab, dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Diabetic Macular Edema
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.
- Trial name
- NCT00168337
- Testing
- Dexamethasone
- Where
- 14 sites in United States, Brazil and 12 more
- Volunteers
- 554 people
- Sponsor
- Allergan
Diabetic Macular Edema, Type 1 Diabetes Mellitus
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- PHOTON (NCT04429503)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 138 sites in United States, Canada and 6 more
- Volunteers
- 660 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
- Trial name
- NCT02121262
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 18 sites in China, Philippines
- Volunteers
- 284 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Edema
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
The study involves the enrollment of patients over 18 years of age with diabetic macular edema(DME). Patients with one study eye will be randomly assigned (stratified by visual acuity and prior laser) with equal probability to…
- Trial name
- IVT (NCT00367133)
- Testing
- Standard of Care Group, 1mg triamcinolone acetonide, 4mg triamcinolone acetonide
- Where
- 84 sites in United States
- Volunteers
- 840 people
- Sponsor
- Jaeb Center for Health Research
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration
SD-OCT Angiography
The objective of this study is to image retinal vascular alterations in patients with retinal disease using the AngioVue OCT-A system and understand the information these images provide.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT02510885
- Testing
- AngioVue SD-OCT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Diabetic Macular Edema
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
Researchers are looking for a better way to treat people who have diabetic macular edema (DME). Diabetic macular edema (DME) is a complication of diabetes.
- Trial name
- VISION-AF (NCT05511038)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 10 sites in India
- Volunteers
- 100 people
- Sponsor
- Bayer
Diabetic Macular Edema
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema
- Trial name
- NCT02348918
- Testing
- Luminate 1.0mg, Luminate 2.0mg, Luminate 3.0mg
- Where
- 17 sites in United States
- Volunteers
- 218 people
- Sponsor
- Allegro Ophthalmics, LLC